Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesoblast (MESO) Common Equity: 2015-2022

  • Mesoblast's Common Equity fell 14.51% to $497.0 million in Q2 2022 from the same period last year, while for Jun 2022 it was $497.0 million, marking a year-over-year decrease of 14.51%. This contributed to the annual value of $497.0 million for FY2022, which is 14.51% down from last year.
  • According to the latest figures from Q2 2022, Mesoblast's Common Equity is $497.0 million, which was down 14.51% from $581.4 million recorded in Q2 2021.
  • Mesoblast's 5-year Common Equity high stood at $581.4 million for Q2 2021, and its period low was $481.1 million during Q2 2019.
  • Over the past 3 years, Mesoblast's median Common Equity value was $549.3 million (recorded in 2020), while the average stood at $542.6 million.
  • Per our database at Business Quant, Mesoblast's Common Equity grew by 14.19% in 2020 and then dropped by 14.51% in 2022.
  • Over the past 5 years, Mesoblast's Common Equity (Quarterly) stood at $546.0 million in 2018, then fell by 11.90% to $481.1 million in 2019, then grew by 14.19% to $549.3 million in 2020, then increased by 5.84% to $581.4 million in 2021, then dropped by 14.51% to $497.0 million in 2022.
  • Its last three reported values are $497.0 million in Q2 2022, $581.4 million for Q2 2021, and $549.3 million during Q2 2020.